Text Size

Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT00610415
First received: January 25, 2008
Last updated: January 28, 2013
Last verified: January 2013
History of Changes
  Purpose

To see if a limited sampling of tumor tissue from human subjects is a feasible way to gather adequate tissue for cancer stem cell quantification.


Condition Intervention
Head and Neck Cancer
Head and Neck Cancers
 Procedure: tumor biopsy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Quantification of the cancer stem cell population by flow cytometry [ Time Frame: 1 month ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Tissue samples


Enrollment: 40
Study Start Date: December 2007
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Eligible patients will have a diagnosis of squamous cell carcinoma

Criteria

Inclusion Criteria:1. Patients with malignant tumors seen at the Stanford University Cancer Center. Eligible patients will have a diagnosis of squamous cell carcinoma (HNSCC) and will have been seen in the Stanford Head and Neck Oncology Program. A decision to undergo surgery at Stanford will have been made, prior to recruiting patients for the study, and prior to obtaining the samples during surgery. (Histological confirmation of the diagnosis need not be made prior to obtaining consent.) 2. A definitive resection of a malignant tumor is planned. 3. Surgeon judgment that the definitive procedure will not be compromised by including

  • FNA
  • Core needle biopsy
  • Cup forceps or punch biopsy of<4mm. 4. Informed consent documented prior to procedure
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00610415

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Dr. A. Dimitrios Colevas Stanford University
  More Information

No publications provided

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT00610415     History of Changes
Other Study ID Numbers: ENT0023, 98543, SU-12142007-934, 10514
Study First Received: January 25, 2008
Last Updated: January 28, 2013
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms

ClinicalTrials.gov processed this record on June 17, 2013